olmesartan medoxomil has been researched along with Arterial Occlusive Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cui, TX; Horiuchi, M; Iwai, M; Li, JM; Liu, HW; Okumura, M; Takeda-Matsubara, Y; Wu, L | 1 |
| Cui, TX; Horiuchi, M; Iwai, M; Jinno, T; Li, JM; Li, Z; Liu, HW; Ogihara, T; Rakugi, H | 1 |
2 other study(ies) available for olmesartan medoxomil and Arterial Occlusive Diseases
| Article | Year |
|---|---|
Effect of estrogen and AT1 receptor blocker on neointima formation.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Arterial Occlusive Diseases; Cardiotonic Agents; Cell Division; DNA; DNA-Binding Proteins; Estradiol; Female; Imidazoles; Male; Mice; Mice, Inbred C57BL; Mitogen-Activated Protein Kinases; Muscle, Smooth, Vascular; Olmesartan Medoxomil; Phosphorylation; Receptor, Angiotensin, Type 1; Sex Factors; STAT1 Transcription Factor; STAT3 Transcription Factor; Tetrazoles; Trans-Activators | 2002 |
Calcium channel blocker azelnidipine enhances vascular protective effects of AT1 receptor blocker olmesartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Arterial Occlusive Diseases; Azetidinecarboxylic Acid; Calcium Channel Blockers; Cell Division; Dihydropyridines; Drug Synergism; Drug Therapy, Combination; Imidazoles; Inflammation; Male; MAP Kinase Signaling System; Mice; Mice, Knockout; Muscle, Smooth, Vascular; Olmesartan Medoxomil; Oxidative Stress; Receptor, Angiotensin, Type 1; Tetrazoles; Tunica Intima | 2004 |